Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Marbofloxacin; Clotrimazole; Dexamethasone acetate
Krka, d.d., Novo mesto
QS02CA06
Marbofloxacin; Clotrimazole; Dexamethasone acetate
3, 10, 1 milligram(s)/millilitre
Ear drops, suspension
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
dexamethasone and antiinfectives
Not Currently Available
Authorised
2017-01-20
Health Products Regulatory Authority 21 January 2022 CRN00C9G8 Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Otoxolan ear drops, suspension for dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains: ACTIVE SUBSTANCES: Marbofloxacin 3.0 mg Clotrimazole 10.0 mg Dexamethasone acetate 1.0 mg (equivalent to Dexamethasone 0.9 mg) EXCIPIENTS: Propyl gallate (E310) 1.0 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Ear drops, suspension. Off yellow, opalescent, viscous suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of otitis externa of both bacterial and fungal origin respectively due to bacteria sensitive to marbofloxacin, and fungi especially _Malassezia pachydermatis_ sensitive to clotrimazole. 4.3 CONTRAINDICATIONS Do not use in dogs suffering from perforation of the tympanic membrane. Do not use in cases of hypersensitivity to the active substances, to other azole antifungal agents or to any other fluoroquinolones or to any of the excipients. Do not use in animals, where resistance of causative agents to marbofloxacin and/or clotrimazole is known. See section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Bacterial and fungal otitis is often secondary in nature. The underlying cause should be identified and treated. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Before treating with the product, the integrity of the tympanic membrane must be verified. Use of the product should be based on susceptibility testing of the bacteria and/or fungi isolated from the animal. If this is not possible, therapy should be based on local (regional) epidemiological information about susceptibility of the target pathogens. Official and local antimicrobial policies should be taken in to account when the veterinary medicinal product is used. Health Products Regulatory Authority 21 January 2022 CRN00C9G8 Page 2 of 4 Heavy reliance on a si Read the complete document